Cargando…

Advanced Glycation End Products in Infant Formulas Do Not Contribute to Insulin Resistance Associated with Their Consumption

INTRODUCTION: Infant formula-feeding is associated with reduced insulin sensitivity. In rodents and healthy humans, advanced glycation end product (AGE)-rich diets exert diabetogenic effects. In comparison with human breast-milk, infant formulas contain high amounts of AGEs. We assessed the role of...

Descripción completa

Detalles Bibliográficos
Autores principales: Klenovics, Kristína Simon, Boor, Peter, Somoza, Veronika, Celec, Peter, Fogliano, Vincenzo, Šebeková, Katarína
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3534663/
https://www.ncbi.nlm.nih.gov/pubmed/23301020
http://dx.doi.org/10.1371/journal.pone.0053056
_version_ 1782475377918083072
author Klenovics, Kristína Simon
Boor, Peter
Somoza, Veronika
Celec, Peter
Fogliano, Vincenzo
Šebeková, Katarína
author_facet Klenovics, Kristína Simon
Boor, Peter
Somoza, Veronika
Celec, Peter
Fogliano, Vincenzo
Šebeková, Katarína
author_sort Klenovics, Kristína Simon
collection PubMed
description INTRODUCTION: Infant formula-feeding is associated with reduced insulin sensitivity. In rodents and healthy humans, advanced glycation end product (AGE)-rich diets exert diabetogenic effects. In comparison with human breast-milk, infant formulas contain high amounts of AGEs. We assessed the role of AGEs in infant-formula-consumption-associated insulin resistance. METHODS: Total plasma levels of N(ε)-(carboxymethyl)lysine (CML), AGEs-associated fluorescence (λ(ex) = 370 nm/λ(em) = 445 nm), soluble adhesion molecules, markers of micro- binflammation (hsCRP), oxidative stress (malondialdehyde, 8-isoprostanes) and leptinemia were determined, and correlated with insulin sensitivity in a cross-sectional study in 166 healthy term infants aged 3-to-14 months, subdivided according to feeding regimen (breast-milk- vs. infant formula-fed) and age (3-to-6-month-olds, 7-to-10-month-olds, and 11-to-14-month-old infants). Effects of the consumption of low- vs. high-CML-containing formulas were assessed. 36 infants aged 5.8±0.3 months were followed-up 7.5±0.3 months later. RESULTS: Cross-sectional study: 3-to-6-month-olds and 7-to-10-month-old formula-fed infants presented higher total plasma CML levels and AGEs-associated fluorescence (p<0.01, both), while only the 3-to-6-month-olds displayed lower insulin sensitivity (p<0.01) than their breast-milk-fed counterparts. 3-to-6-month-olds fed low-CML-containing formulas presented lower total plasma CML levels (p<0.01), but similar insulin sensitivity compared to those on high-CML-containing formulas. Markers of oxidative stress and inflammation, levels of leptin and adhesion molecules did not differ significantly between the groups. Follow-up study: at initial investigation, the breast-milk-consuming infants displayed lower total plasma CML levels (p<0.01) and AGEs-associated fluorescence (p<0.05), but higher insulin sensitivity (p<0.05) than the formulas-consuming infants. At follow-up, the groups did not differ significantly in either determined parameter. CONCLUSIONS: In healthy term infants, high dietary load with CML does not play a pathophysiological role in the induction of infant formula-associated insulin resistance. Whether a high load of AGEs in early childhood affects postnatal programming remains to be elucidated.
format Online
Article
Text
id pubmed-3534663
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-35346632013-01-08 Advanced Glycation End Products in Infant Formulas Do Not Contribute to Insulin Resistance Associated with Their Consumption Klenovics, Kristína Simon Boor, Peter Somoza, Veronika Celec, Peter Fogliano, Vincenzo Šebeková, Katarína PLoS One Research Article INTRODUCTION: Infant formula-feeding is associated with reduced insulin sensitivity. In rodents and healthy humans, advanced glycation end product (AGE)-rich diets exert diabetogenic effects. In comparison with human breast-milk, infant formulas contain high amounts of AGEs. We assessed the role of AGEs in infant-formula-consumption-associated insulin resistance. METHODS: Total plasma levels of N(ε)-(carboxymethyl)lysine (CML), AGEs-associated fluorescence (λ(ex) = 370 nm/λ(em) = 445 nm), soluble adhesion molecules, markers of micro- binflammation (hsCRP), oxidative stress (malondialdehyde, 8-isoprostanes) and leptinemia were determined, and correlated with insulin sensitivity in a cross-sectional study in 166 healthy term infants aged 3-to-14 months, subdivided according to feeding regimen (breast-milk- vs. infant formula-fed) and age (3-to-6-month-olds, 7-to-10-month-olds, and 11-to-14-month-old infants). Effects of the consumption of low- vs. high-CML-containing formulas were assessed. 36 infants aged 5.8±0.3 months were followed-up 7.5±0.3 months later. RESULTS: Cross-sectional study: 3-to-6-month-olds and 7-to-10-month-old formula-fed infants presented higher total plasma CML levels and AGEs-associated fluorescence (p<0.01, both), while only the 3-to-6-month-olds displayed lower insulin sensitivity (p<0.01) than their breast-milk-fed counterparts. 3-to-6-month-olds fed low-CML-containing formulas presented lower total plasma CML levels (p<0.01), but similar insulin sensitivity compared to those on high-CML-containing formulas. Markers of oxidative stress and inflammation, levels of leptin and adhesion molecules did not differ significantly between the groups. Follow-up study: at initial investigation, the breast-milk-consuming infants displayed lower total plasma CML levels (p<0.01) and AGEs-associated fluorescence (p<0.05), but higher insulin sensitivity (p<0.05) than the formulas-consuming infants. At follow-up, the groups did not differ significantly in either determined parameter. CONCLUSIONS: In healthy term infants, high dietary load with CML does not play a pathophysiological role in the induction of infant formula-associated insulin resistance. Whether a high load of AGEs in early childhood affects postnatal programming remains to be elucidated. Public Library of Science 2013-01-02 /pmc/articles/PMC3534663/ /pubmed/23301020 http://dx.doi.org/10.1371/journal.pone.0053056 Text en © 2013 Klenovics et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Klenovics, Kristína Simon
Boor, Peter
Somoza, Veronika
Celec, Peter
Fogliano, Vincenzo
Šebeková, Katarína
Advanced Glycation End Products in Infant Formulas Do Not Contribute to Insulin Resistance Associated with Their Consumption
title Advanced Glycation End Products in Infant Formulas Do Not Contribute to Insulin Resistance Associated with Their Consumption
title_full Advanced Glycation End Products in Infant Formulas Do Not Contribute to Insulin Resistance Associated with Their Consumption
title_fullStr Advanced Glycation End Products in Infant Formulas Do Not Contribute to Insulin Resistance Associated with Their Consumption
title_full_unstemmed Advanced Glycation End Products in Infant Formulas Do Not Contribute to Insulin Resistance Associated with Their Consumption
title_short Advanced Glycation End Products in Infant Formulas Do Not Contribute to Insulin Resistance Associated with Their Consumption
title_sort advanced glycation end products in infant formulas do not contribute to insulin resistance associated with their consumption
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3534663/
https://www.ncbi.nlm.nih.gov/pubmed/23301020
http://dx.doi.org/10.1371/journal.pone.0053056
work_keys_str_mv AT klenovicskristinasimon advancedglycationendproductsininfantformulasdonotcontributetoinsulinresistanceassociatedwiththeirconsumption
AT boorpeter advancedglycationendproductsininfantformulasdonotcontributetoinsulinresistanceassociatedwiththeirconsumption
AT somozaveronika advancedglycationendproductsininfantformulasdonotcontributetoinsulinresistanceassociatedwiththeirconsumption
AT celecpeter advancedglycationendproductsininfantformulasdonotcontributetoinsulinresistanceassociatedwiththeirconsumption
AT foglianovincenzo advancedglycationendproductsininfantformulasdonotcontributetoinsulinresistanceassociatedwiththeirconsumption
AT sebekovakatarina advancedglycationendproductsininfantformulasdonotcontributetoinsulinresistanceassociatedwiththeirconsumption